Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer

Published:2021-01-13 Issue:1 Volume:4 Page:e2027764
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Ramagopalan Sreeram V.¹,Pisoni Riccardo²,Rathore Lokendra Singh³,Ray Joshua¹,Sammon Cormac⁴

Affiliation:

1. Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland

2. Pharma International Informatics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

3. Strategic Insights & Advance Analytics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

4. PHMR Ltd, London, United Kingdom

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2774899/ramagopalan_2021_ld_200178_1609792938.99074.pdf

Reference6 articles.

1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.;Swain;Lancet Oncol,2020

2. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer.;Khozin;Cancer,2019

3. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.;Guyot;BMC Med Res Methodol,2012

4. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.;Quan;Med Care,2005

5. Efficacy, patterns of use and cost of pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: the National Cancer Centre Singapore experience.;Rahardja;World J Clin Oncol,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice;World Journal of Oncology;2024-06

2. Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model;Scientific Reports;2022-11-28

3. Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer;Cancer Research and Treatment;2022-10-15

4. Aptamer‐siRNA chimeras: Promising tools for targeting HER2 signaling in cancer;Chemical Biology & Drug Design;2022-09-25

5. Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer;JAMA Network Open;2022-02-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3